Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Clover Bio Awarded Manufacturing Permit for S-Trimer COVID-19 Vaccine

publication date: Sep 9, 2021
 | 
author/source: Richard Daverman, PhD

Chengdu Clover Biopharma received a manufacturing permit for its S-Trimer COVID-19 vaccine candidate at its Changxing facility. Clover is currently testing the vaccine in a global pivotal Phase II/III trial as a combination of the SCB-2019 antigen (a stabilized trimeric form of the S-protein) and two adjuvants. It is based on the original strain of the SARS-CoV-2 virus. Clover plans to submit for conditional approval of SCB-2019 in China and the EU, plus WHO, with a launch as early as year-end 2021. At peak capacity, the Changxing facility will be able to produce more than one billion doses of antigen per year.

To produce the vaccine, Clover's SCB-2019 antigen is combined with two adjuvants: Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum).

Clover's in-house, commercial-ready Changxing biologics facility is a part of Zhejiang Clover Biopharmaceutical, a wholly owned Clover subsidiary. It has a centrally-automated and flexible start-to-finish platform based on single-use technologies. The  facility was designed to adhere to current Good Manufacturing Practices (cGMP) standards in accordance with NMPA, FDA, and EMA regulations.

SCB-2019 (CpG 1018/Alum), Clover's COVID-19 vaccine candidate, could be one of the first protein-based COVID-19 vaccines commercialized globally through the COVAX Facility.

Clover uses its Trimer-Tag™ technology platform to develop novel vaccines and biologic therapeutic candidates. In 2020, the company received a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) for up to $328 million to support development of the COVID-19 vaccine.

See our other articles on Clover Bio.

Disclosure: None.

 


 

Share this with colleagues:

 

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China